MALVERN, Pa. /New York Netwire/ — Reaction Biology Corporation (“RBC”), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
The enzymes offered for sale are active and validated for use in high-throughput screening assays. In the case of the HMTs those assays employ RBC’s proprietary HotSpot(SM) methodology, which couples economical screening with the data quality of a “gold standard” radiometric approach. HMTs are also routinely assayed by conventional scintillation counting in a plate format (TopCount).
“Our assay expertise is helping us make better enzymes, while the ability to produce new proteins in-house will help us expand the range of assays we can offer, and provide our clients with a more complete drug discovery process,” said Konrad Howitz, RBC’s Director of Epigenetics.
In addition to the HDAC, Sirtuin, HMT, DNMT and HAT assays currently offered, RBC has innovative assays for demethylases and epigenetic readers in active development.
Based in Malvern, PA, RBC has become a premier provider of drug screening and profiling services. With more than 400 kinases, RBC’s coverage of the kinome is the broadest in the industry. Using its proprietary HotSpot technology and other innovations, RBC is expanding its already substantial coverage of epigenetic regulatory enzymes. RBC has provided its services to over 200 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
For more information, visit: http://www.reactionbiology.com .
Copyright © 2011 New York Netwire™ and Neotrope®. NewYorkNetwire™ is a news publication of the Neotrope News Network and a trademark of Neotrope – all rights reserved. NEWS SOURCE: Reaction Biology Corporation
